Recent in vitro study on lung cells with SARS-CoV-2 shows virus-blocking efficacy of bitop Ectoin®. Further information on the inhibition of the binding of the spike protein of SARS-CoV-2 can be found in this PDF.
Our BioStab Peroxidase Conjugate Stabilizer is used for COVID-19 ELISA test kits. We send our thoughts and prayers to everybody, who is affected by this virus and would like to express our gratitude to all the heroes, who are fighting in the front-rows during these difficult times. Thank you!
We spent some inspiring days in China and had the chance to visit our partner POLY STATE BEAUTY. During the guided tour of the company and the laboratories, we learnd a lot about the company. Thank you for the great meetings and interesting conversations.
On 5th to 7th November the in-cosmetics Asia took place at Bangkok International Trade & Exhibition Centre in Thailand
On 23th to 25th October the SEPAWA Congress took place at the Estrel Congress & Exhibition Center Berlin, Germany
Dortmund, 29.05.2019: White sugar, table sugar or—nerdy—sucrose is at the centre of the EU project “CARBAFIN”. The EU is the world’s leading producer of sugar from sugar beet. Due to societal changes and changes in market regulations the European sugar beet industry faces big challenges. 145,000 sugar beet farmers in 20 EU member states and approximately 28,000 jobs in the direct processing of sugar beets alone are at risk. These changes led to an annual sugar beet surplus of at least 300,000 t and the goal of CARBAFIN is to use this very surplus by putting the sugar to use in new value chains in a bio-based economy. Since CARBAFIN is an EU project, partners are located in different EU countries, one even from Switzerland:
- acib GmbH, Austria
- Graz University of Technology, Austria
- Pfeifer & Langen GmbH & Co. KG, Germany
- AVA Biochem BSL AG, Switzerland
- Ghent University, Belgium
- bitop AG, Germany
- Galab Laboratories GmbH, Germany
- PNO Consultants BV, Netherlands
The project receives total funds of 5.3 million € and we at bitop are using funds for the development of the Glycoin® process and for the production of Glycoin®.
The Glycoin® Sugar Connection
Chemically, Glycoin® is a quite simple molecule which can be viewed as a simple combination of dextrose (nerdy: glucose) and glycerol. Unfortunately, production is not as simple, because mixing glucose and glycerol is by far not enough to start a reaction towards Glycoin®. For reasons too complicated for such a news, bitop requires sucrose as the raw material, a molecule composed of glucose and fruit sugar (nerdy: fructose). The cleavage of the bond between the two sugars is what drives the reaction to bind glycerol to glucose—at the right spot! Within the framework of CARBAFIN, the focus lies on the Glycoin ® production at industrial scale as an example for the already mentioned “new value chains” to show that the raw material sucrose can be used to produce the value product Glycoin®. bitop received funding for a lab-scale purification unit for improving the Glycoin® process. Furthermore, the full Glycoin® process will be assessed and analysed ecologically and economically by LCA experts from Graz University of Technology.
The project started in 2018 and will end in 2021 and within this timeframe you can expect further news from bitop and the other members of the consortium.
Dortmund, 22.01.2019. With the beginning of 2019 bitop starts into a new year full of technological innovations and developments. This comes along with the appointment of its new CEO - Michael Braig, who started in January 2019 and brought a breath of fresh air combined with a strong track-record in sales, marketing and business development to the well-established company. Before joining bitop, Michael Braig was leading the Consumer Care Business of Galderma (Nestlé Skin Health) for 3 years. Prior to Galderma, he spent almost 5 years with Reckitt Benckiser, where he was responsible for the Health Care Business in Germany.
Dortmund, 07.09.2018. Just in time for its 25th anniversary, bitop AG is opening a new chapter: The manufacturer of natural protection molecules for skin and mucosa is expanding at its new location in Dortmund. At the opening event, bitop was welcoming around 200 guests from Germany and abroad. The products of bitop are part of many well-known cosmetics and medical devices. The substances obtained from special bacteria - so-called Extremolytes - are successfully marketed worldwide. They are used inter alia for the treatment of allergies, skin and respiratory diseases. The cosmetics industry uses bitop's products, for example, in the areas of anti-aging, skin soothing and pollution protection.
"With the move from Witten to the biotechnology location in Dortmund, we are also becoming visible to the outside world as a highly specialized, global biotech company," explains Claus Kjærsgaard, who has been the new CEO of bitop AG since June 2018. "Our newly built high-tech company building provides much-needed space for growth and also laboratories for young start-ups, as we ourselves once were. Most importantly, after the completion of the ongoing approval process, we will soon be building our new production facility, which will enable us to produce more sustainably, more effectively, and at lower cost. "
From its new location, bitop wants to open up new markets and thus further expand its position as world market leader in the segment of natural extremolytes. "With our medical devices, we are currently represented in around 50 countries, our active cosmetic ingredients are available worldwide" says the new CEO. "Above all, markets in Asia will be the focus of our interest in the coming years". The new process will also give new applications for bitop's products. A personnel expansion of currently over 50 to about 70 employees is planned in the next step.
"With the help of special nanofiltration technology, we will be able to gain our highly effective extremolytes more effective, cheaper and, above all, far more sustainable in the future.“ explains Andreas Bilstein. The scientific director of bitop AG has been taking care of the technical needs of the company, which was founded 25 years ago as a spin-off of the University of Witten-Herdecke.
"With the new process one can forego many stages of the previous production process. This saves us considerable amounts of chemicals, energy, water and activated carbon and thus protects the environment, "says Bilstein, summing up the main advantages of the new process.
bitop will invest around EUR 5.5 million in the new production facility, which will be installed in the newly constructed high-tech building following completion of the ongoing approval process. The start of production is expected in the second quarter of 2019.
"The new process will also enable new applications of our extremolytes - especially in the cosmetics industry," predicts Bilstein. Details will be evaluated in the coming months.
The 25th company anniversary was celebrated on September 5th for a whole day with a total of 200 invited guests from the cosmetics, pharma and animal health and care industry. During an in-house exhibition, the guests had the chance to peek behind the scenes of bitop and get in touch with all employees and departments. In the afternoon, bitop has presented three scientific and business-related lectures in all the topic areas which interest the industry. The keynote speech was given by Prof. Dr. Jean Krutmann, who spoke about the clinical efficacy of Ectoin® for dermatological and anti-pollution applications. The scientific program was followed by a cocktail reception.
Here you can download the press release .
Dortmund, 06.08.2018: bitops partner in Hungary, Phytotec Hungária, has recently launched the Ectoin® Mouth Wash under its brand Endoral®. This is the first commercial launch of the highly effective solution against Stomatitis and Mucositis. The product has been tested in human and performed extraordinarily well. It is not only suitable for the treatment of dry mucosa in healthy patients but also very effective for the prevention and treatment of chemotherapy-induced mucositis. Phytotec positions the product for the treatment of dry mouth and stomatitis. These diseases can have several causes. The most common ones are diabetes, aging and autoimmune diseases like the Sjörgen-syndrome.
Ectoin® Mouth wash is supported by the following, clinically proven claims:
- Supports reduction of inflammations of oral mucous membranes (oral mucositis or stomatitis)
- Helps to reduce the incidence of inflamed oral mucosa
- Alleviates and prevents symptoms such as sore mouth and redness and burning of the oral mucosa
- Helps to relieve pain in the mouth and therefore eases eating, drinking, and talking
- Supports the regeneration process of damaged oral mucosa
- Moistens dry mouth and prevents dehydration
- Cleans the mouth
- Effects based on 100% natural ingredients
Interested in a license? Please contact: firstname.lastname@example.org
New study in Oncology Supportive Care published:
Patients prefer Ectoin® Mouth Wash over standard treatment (Caphosol®)
Dortmund/ Hungary, 07.06.2018: bitop is proud to announce that another successful observational study has been conducted with one of its Ectoin®-containing products. The recently published study compared Ectoin® Mouth Wash with the standard-of-care calcium phosphate mouthwash Caphosol® for the treatment of chemotherapy-induced oral mucositis. 80 % of patients using Ectoin® Mouth Wash were entirely symptom-free after 3 weeks of treatment, compared to only 43 % in the Caphosol® group. Moreover, Patients preferred Ectoin® Mouth Wash over calcium phosphate mouthwash. The study shows that Ectoin® Mouth Wash is tolerable and effective for the treatment of mucositis.
Dr. Zoltán Baráth, Pulmologist at National Korányi Institute of TBC and Pulmology in Budapest worked on the study and states:
“We are very proud that we can now offer cancer patients an innovative and effective treatment for oral mucositis whose efficacy proved to go even beyond the efficacy of the well-known standard treatment Caphosol®. Taken preventively, we might even protect patients against this painful condition. We are sure that, with Ectoin® Mouth Wash, we can make life more worth living for cancer patients.”
If you are interested in in-licensing one of bitop's products, please contact us: email@example.com
Dortmund/ Canada, 30.05.2018: Since march, also Canadians can benefit from the soothing effects of Ectoin® in the case of allergic eye irritation. Bayer Canada launched hydraSense® Drops - Allergy Therapy. The innovative formulation with Ectoin® and hyaluronic acid lubricates, hydrates and protects the eyes. The clinically proven, naturally-sourced ingredient Ectoin® helps to relieve itchy, watery eyes and burning sensation due to allergies. Like all Ectoin® containing eye drops, the product is preservative-free and can be used with contact lenses.
bitop’s Ectoin® Allergy Eye Drops have been clinically proven to show significant reduction of local symptoms during allergic conjunctivitis. They have been tested against standard OTC drugs and placebo and show comparable efficacy as Azelastine and Ketotifen-containing eye drops. The excellent tolerability in children and adults completes the superiority of Ectoin®. Click here to read more about bitop’s Ectoin® Allergy products.
If you are interested in in-licensing one of bitop's products, please contact us: firstname.lastname@example.org
Dortmund, 03.05.2018: The original manufacturer of Ectoin® and Glycoin® natural will present its brand-new innovations on the Vitafoods 2018. Visit the bitop booth T-142 to get an exclusive sneak peek into the product developments and innovation pipeline. This year, Pulmonology, Ophthalmology and Animal Health are in the focus.
The SoftBreezer® combines the power of bitops Ectoin® Inhalation Solution with the device know-how of Ursatec. The portable inhaler will be released soon with a randomized clinical trial studying air pollution-induced lung disease.
The Ophthalmology line will be upgraded by the Ectoin® Eye Spray on the basis of colloids. This worldwide innovation uses colloids as a carrier system for the substance Ectoin®. A clinical trial is currently running to prove the superiority of Ectoin® Eye Spray over the German market leader.
bitop is pleased to present its Animal Health and Care portfolio that consists of two new product lines: Ectoin® pet and Ectoin® equi. The ranges have been specifically developed for man´s best friends: dogs, cats, small pets as well as horses, ponies and donkeys. All products are developed in Germany and manufactured in accordance with highest quality standards, following ISO13485.
Interested parties will get the chance to inform themselves about those pioneer products and the opportunity to get the distribution license in every country worldwide. Contact us to arrange a meeting or just come by our booth.
Meet us at
PCHi in Shanghai,
2-4 June 2020
Meet us in Shanghai at stand 1S47 (shared with ToOne Chemical).
in-cosmetics Korea in Seoul,
17-19 June 2020
Meet us in Seoul at stand M10 (shared with DKSH).
in-cosmetics global Barcelona,
6-8 October 2020
Meet us in Barcelona at stand T20
Cosme Tech in Tokyo,
20-22 January 2020
Meet us in Tokyo at stand #40-44 (shared with Higuchi Inc.).
CPhI worldwide in Frankfurt,
5-7 November 2019
Meet us in Frankfurt at stand 90D53 (shared with BBT Biotech GmbH).
SEPAWA CONGRESS in Berlin,
23-25 October 2019
Meet us and our distributor C.H. Erbslöh at stand B374 – 375.
in-cosmetics North America in NYC,
23-24 October 2019
Meet us in Manhatten at booth B40 (shared with Mibelle).
in-cosmetics Korea in Seoul,
26-28 June 2019
Meet us in Seoul at stand K10 (shared with DKSH).
Vitafoods Europe in Geneva,
07-09 May 2019
Meet us in Geneva at stand T156.
Suppliers' day in New York,
07-08 May 2019
Meet us in New York at stand 215.
in-cosmetics global in Paris,
02-04 April 2019
Meet us in Paris at stand N12.